Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE.
DUETACT vs ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, muscle, and liver. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
Oral, initial: rosiglitazone 2 mg plus metformin 500 mg twice daily; maximum: rosiglitazone 8 mg plus metformin 2000 mg per day (divided twice daily).
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Metformin: 4-8.7 h (elimination), prolonged in renal impairment; Rosiglitazone: 3-4 h (terminal), slightly longer in hepatic impairment.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Metformin: 90% renal unchanged via tubular secretion; Rosiglitazone: 64% renal (metabolites), 23% fecal. Combined: minimal biliary excretion.
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione